3 min read
Measuring What Can't Be Seen: How PTSD Clinical Trials Prove a Drug Works
When an oncology drug is tested, the signal is often brutally clear. A tumor either shrinks on a scan or it does not. A...
đŸ”¬ Connecting with the Global Clinical Data and Biostatistics Community
Veristat is pleased to attend PHUSE US Connect 2026, where leaders in biostatistics, statistical programming, data science, and regulatory standards gather to advance innovation in clinical development.
As clinical programs grow more complex and regulatory expectations around data quality continue to evolve, sponsors need statistical leadership and data strategies that transform study data into clear, submission-ready evidence. Events like PHUSE bring together the experts shaping how data standards, analytics, and statistical thinking support better regulatory outcomes.
Our team looks forward to connecting with fellow data and statistical professionals and discussing how strong evidence strategies can support efficient clinical development.
đŸ‘¥ Meet the Veristat Team at PHUSE US Connect
Connect with our experts to explore how Veristat’s tailored solutions can advance your clinical and regulatory milestones:
-
Mark McBride, VP Global Biostatistics and Programming
đŸ“… Schedule a meeting in advance
By completing the form on this page. We welcome the opportunity to discuss your upcoming programs and how Veristat can be a strategic partner in your success.
đŸ’¡ Our Expertise
Whether you're launching a first-in-human study or navigating complex regulatory pathways, Veristat delivers integrated expertise and personalized support across the development lifecycle:
Let’s shape the future of clinical research—together.
Schedule A Meeting
Meet with us at PHUSE US Connect 2026
3 min read
The Psychedelic Setback: What MDMA Rejection Taught Drug Developers
Apr 24, 2026 Veristat Blog
In August 2024, the FDA declined to approve MDMA-assisted therapy for post-traumatic stress disorder. The decision...